
51 - 200 employees
Founded 2020
🏥 Healthcare
🧬 Biotechnology
💊 Pharmaceuticals
💰 $100M Post-IPO Equity on 2022-12
Healthcare • Biotechnology • Pharmaceuticals
Erasca, Inc. is a clinical-stage precision oncology company committed to eradicating cancer by targeting one of cancer's most commonly mutated pathways, the RAS/MAPK pathway. The company is dedicated to developing a modality-agnostic portfolio of therapeutic programs designed to thoroughly shut down the RAS/MAPK pathway, which affects millions of lives globally each year. Erasca is advancing a robust pipeline with the potential to transform cancer treatment and improve the lives of patients suffering from various types of cancer. With a focus on groundbreaking science in oncology, Erasca aims to bring new hope to patients and lead the way in precision oncology innovations.
Selected: 🆕 Date Added.
🕒 September 24
Clinical oncology executive leading Erasca’s pancreatic and colorectal cancer drug-development programs. Guiding trials, regulatory strategy, safety, and GI cancer clinical teams.
🏄 California – Remote
💵 $390k - $435k / year
💰 $100M Post-IPO Equity on 2022-12
⏰ Full Time
🟠 Senior
✨ SVP
👻 Ghost score 2%
🕒 May 14
SVP Biometrics overseeing biostatistics and clinical data management at Erasca. Leading teams from IND-enabling to registration and launch phases.
🏄 California – Remote
💵 $350k - $415k / year
💰 $100M Post-IPO Equity on 2022-12
⏰ Full Time
🔴 Lead
✨ SVP
👻 Ghost score 29%